Rsv-specific binding molecule

ABSTRACT

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.

This application is a continuation patent application of U.S. patentapplication Ser. No. 15/042,656, filed on Feb. 12, 2016, which is acontinuation patent application of U.S. patent application Ser. No.14/039,148, filed on Sep. 27, 2013, which is a continuation patentapplication of U.S. patent application Ser. No. 12/898,325, filed onOct. 5, 2010, which claims priority to U.S. Provisional PatentApplication No. 61/278,358, filed Oct. 6, 2009, each of which isincorporated herein by reference.

SEQUENCE LISTING

This application contains a Sequence Listing electronically submitted tothe United States Patent and Trademark Office via EFS-Web as an ASCIItext file entitled “490-00020104_SequenceListing_ST25.txt” having a sizeof 16 kilobytes and created on Jul. 26, 2018. Due to the electronicfiling of the Sequence Listing, the electronically submitted SequenceListing serves as both the paper copy required by 37 CFR § 1.821(c) andthe CU required by § 1.821(c). The information contained in the SequenceListing is incorporated by reference herein.

The invention relates to the fields of biology and medicine.

Respiratory Syncytial Virus (RSV) is a common cold virus belonging tothe family of paramyxovirus. RSV is virulent, easily transmissible andthe most common cause of lower respiratory tract disease in children ofless than 2 years of age. Up to 98% of children attending day care willbe infected in a single RSV season, Between 0.5% and 3.2% of childrenwith RSV infection require hospitalization. Approximately 90,000hospital admissions and 4500 deaths per year were reported in UnitedStates. Major risk factors for hospitalization due to RSV are prematurebirth, chronic lung disease, congenital heart disease, compromisedimmunity, and age younger than 6 weeks in otherwise healthy children. Noeffective treatment of RSV positive bronchiolitis beside supportive carein the form of adequate nutrition and oxygen therapy is available,Antiviral therapies such as Ribavirin have not been proven to beeffective in RSV infection. One monoclonal antibody, palivizumab (alsocalled Synagis), is registered for prophylaxis against RSV infection.Palivizumab is a genetically engineered (humanized) monoclonal antibodyto the fusion protein (F protein) of RSV. The F protein of RSV is aviral membrane protein and responsible for fusion of the virion with ahost cell after attachment. In addition, infection of neighboring cellsthrough the formation of syncytia is promoted by the F protein and itsfunction is thought to depend on the original oligomeric structure ofthe protein. However, palivizumab is not always effective. Therefore,there is a need in the art for alternative and/or supplementaryantibodies and therapies against RSV.

It is an object of the invention to provide improved antibodies againstRSV, or functional equivalents of such antibodies. It is a furtherobject to provide supplementary antibodies against RSV, which, incombination with existing RSV-specific antibodies, provide a synergisticeffect. It is a further object of the invention to provide human orhumanized antibodies or functional equivalents against the RSV F proteinwhich are directed against an epitope that is different from theepitopes that known RSV-specific antibodies are directed against.

Accordingly, the present invention provides an isolated, synthetic orrecombinant antibody or a functional part, derivative and/or analoguethereof which is capable of specifically binding Respiratory SyncytialVirus and which comprises:

a heavy chain CDR1 sequence comprising a sequence which is at least 70%identical to the sequence KLSIH (SEQ ID NO:4), and/or

a heavy chain CDR2 sequence comprising a sequence which is at least 70%identical to the sequence GYEGEVDEIFYAQKFQH (SEQ ID NO:8), and/or

a heavy chain CDR3 sequence comprising a sequence which is at least 70%identical to the sequence LGVTVTEAGLGIDDY (SEQ ID NO:12), and/or

a light chain CDR1 sequence comprising a sequence which is at least 70%identical to the sequence RASQIVSRNHLA (SEQ ID NO:20), and/or

a light chain CDR2 sequence comprising a sequence which is at least 70%identical to the sequence GASSRAT (SEQ ID NO:24), and/or

a light chain CDR3 sequence comprising a sequence which is at least 70%identical to the sequence LSSDSSI (SEQ ID NO:28).

The present invention provides an antibody designated “AM22”, which hasheavy chain and light chain sequences as depicted in FIG. 2. The CDRsequences of AM22, which in particular contribute to the antigen-bindingproperties of AM22, are also depicted in FIG. 2. Antibody AM22 is fullyhuman, is capable of specifically binding RSV (FIG. 3) and is thereforepreferred for prophylactic and/or therapeutic use for human individuals.

As mentioned above the only available clinically used anti-RSV antibodyis palivizumab. This is a humanized monoclonal antibody directed againstan epitope in the antigenic site of the F protein of RSV. Humanizedantibodies still contain part of a mouse antibody and althoughimmunogenic properties are diminished as compared to fully mouseantibodies, side-effects of humanized antibodies may occur when appliedin humans. The present inventors, however, succeeded in obtaining andculturing human B-cells producing RSV-specific antibodies, so that humanRSV-specific antibodies have been provided, that have stronglyreduced—if at all—immunogenic activity as a result of the completelyhuman sequence. As shown in the examples, antibodies according to theinvention have superior characteristics as compared to palivizumab (FIG.1 and table 1). The present inventors have shown that Cotton rats(Sigmodon hispidus) given antibodies according to the invention byintramuscular injection followed by intranasal challenge with RSV-X havea lower Pathology Index than Cotton rats given palivizumab followed bychallenge with RSV-X (FIG. 4C and table 2). The Pathology Index usedherein is a sum of scores to classify three individual markers for lungdamage. These three markers are hyperthropy of bronchus and bronchioliepithelium, inflammation surrounding bronchus and bronchioli(peribronch(iol)itis) and inflammation in the alveoli (alveolitis). Inaddition, Cotton rats injected intramuscularly with antibodies accordingto the invention and subsequent RSV-X challenge had lower lung virustiters than Cotton rats given palivizumab followed by challenge withRSV-X (FIG. 4B), which was determined by TCID50 (50% tissue cultureinfective dose) assay. Hence, AM22 is preferred over palivizumab.

Besides palivizumab, some other RSV-specific antibodies are known. WO2008/147196 discloses sequences of RSV binding molecules, namelyantibodies D25, AM14, AM16 and AM23. As described in detail in example 1of the current application, RSV specific antibody AM22 was obtained fromthe same donor as antibodies D25, AM14, AM16 and AM23. Strikinglyhowever, AM22 recognizes RSV more efficiently than all other antibodiesobtained from the same donor. The IC₅₀ value of AM22, 1.15 ng ml⁻¹, islower than that of palivizumab, D25, AM14, AM16 or AM23. Therefore, theuse of AM22 for treatment and/or prevention of a RSV-related disorderhas advantages over the use of other RSV specific antibodies. Less AM22antibody is necessary to obtain a similar effect compared to the otherantibodies. Therefore, less AM22 has to be administered to an individualfor treatment and/or prevention of a RSV-related disorder.Alternatively, with a similar amount of AM22, as compared to the otherantibodies, a more effective treatment and/or prevention of aRSV-related disorder is achieved.

Furthermore, an RSV-specific antibody according to the present inventionrecognizes a different epitope as the previously disclosed RSV bindingmolecules. AM22, similar to the previously identified antibodies(WO2008/147196), is capable of binding the RSV F protein (FIG. 3A).However, AM22 does not bind a monomeric RSV F protein (FIG. 3B left andright panel). Contrary to AM22, the known antibodies palivizumab andAM16 (disclosed in WO 2008/147196 and FIG. 3B) are capable of bindingthe monomeric form of the F protein. Importantly the AM22 B cell line,expressing the antigen specific B Cell Receptor (BCR) does not recognizea recombinant form of the F protein (FIG. 3C). Thus AM22 binds adifferent epitope of the F protein than palivizumab, D25, AM23 and AM16.When the recombinant F protein was expressed in a vector containing anisoleucine zipper trimerization motif with eight HIS-tags (ILZ-8×HIS),then AM22 recognized this trimeric, conformation dependent structure(FIG. 3D). In contrast AM14 did not recognize either the monomeric formof the F protein or the ILZ-8×HIS F protein. Thus AM22 binds a differentepitope of the F protein than AM14 as well. Furthermore it was foundthat AM22 did not interfere with D25 or palivizumab binding to RSVinfected Hep2 cells. Thus, AM22 binds a different epitope of the Fprotein as compared to D25, AM14, AM16, AM23 and palivizumab. Therefore,RSV-specific antibodies or functional equivalents thereof according tothe present invention are preferably combined with RSV-specificantibodies that are already known, such as palivizumab, D25, AM14, AM16and AM23. By combining an antibody according to the invention with aknown RSV-specific antibody, two or more different epitopes of RSV arerecognized during the same therapy. This way, a stronger immunogenicresponse to RSV is obtained. Furthermore, higher antibody specificityagainst RSV is reached by combining one of the known RSV-specificantibodies with an AM22 antibody according to the invention. With astronger immunogenic response to and higher specificity against RSV,such combination will result in more effective treatment and/orprevention of a RSV-related disorder. Finally, a lower overall antibodydosage is needed because AM22 has a stronger binding capacity for the Fprotein compared to palivizumab, D25, AM14, AM16 and AM23, asdemonstrated by its low IC₅₀ value, of about 1.15 ng/ml.

One embodiment therefore provides an antibody or functional equivalentaccording to the invention which has an IC₅₀ value less than 1.25 ng/mlin an in vitro neutralization assay wherein HEp-2 cells are infectedwith RSV-A2 virus. Said antibody or functional equivalent preferably hasan IC₅₀ value of less than 1.2 ng/ml, preferably between 0.5 ng/ml and1.2 ng/ml. Additionally, an antibody or functional equivalent accordingto the invention preferably has an IC₅₀ value which is at least 120-foldlower, more preferably at least 130-fold lower, than the IC₅₀ value ofpalivizumab in an in vitro neutralization assay wherein HEp-2 cells areinfected with RSV-A2 virus. Said antibody or functional equivalentpreferably has an IC₅₀ value of about 1.15 ng/ml. Thus with anRSV-specific antibody or functional equivalent thereof according to thepresent invention in combination with at least one availableRSV-specific antibody a more effective treatment and/or prevention of aRSV-related disorder is achieved.

A functional equivalent of an antibody is defined herein as a functionalpart, derivative or analogue of an antibody. A functional equivalent ofan antibody is preferably an artificial binding compound, comprising atleast one CDR sequence of an antibody.

A functional part of an antibody is defined as a part which has at leastone same property as said antibody in kind, not necessarily in amount.Said functional part is capable of binding the same antigen as saidantibody, albeit not necessarily to the same extent. A functional partof an antibody preferably comprises a single domain antibody, a singlechain antibody, a single chain variable fragment (scFv), a Fab fragmentor a F(ab′)₂ fragment.

A functional derivative of an antibody is defined as an antibody whichhas been altered such that, at least one property—preferably anantigen-binding property—of the resulting compound is essentially thesame in kind, not necessarily in amount. A derivative is provided inmany ways, for instance through conservative amino acid substitution,whereby an amino acid residue is substituted by another residue withgenerally similar properties (size, hydrophobicity, etc), such that theoverall functioning is likely not to be seriously affected.

A person skilled in the art is well able to generate analogous compoundsof an antibody. This is for instance done using a peptide library orphage display library. Such an analogue has essentially at least onesame property as said antibody in kind, not necessarily in amount.

An antibody according to the invention is preferably a human antibody.The use of human antibodies for prophylaxis and therapy in humansdiminishes the chance of side-effects due to an immunological reactionin a human individual against non-human sequences. In another embodimentan antibody, functional part, derivative or analogue according to theinvention is a humanized antibody. Humanized antibodies are made byincorporating non-human hypervariable domains into human antibodies andtherefore immunogenic properties are diminished as compared to fullynon-human antibodies. In another preferred embodiment an antibody orfunctional part, derivative or analogue according to the invention is achimeric antibody. This way, sequences of interest, such as for instancea binding site of interest, can be included into an antibody orfunctional equivalent according to the invention.

As is well known by the skilled person, a heavy chain of an antibody isthe larger of the two types of chains making up an immunoglobulinmolecule. A heavy chain comprises constant domains and a variabledomain, which variable domain is involved in antigen binding. A lightchain of an antibody is the smaller of the two types of chains making upan immunoglobulin molecule. A light chain comprises a constant domainand a variable domain. The variable domain is, together with thevariable domain of the heavy chain, involved in antigen binding.

Complementary-determining regions (CDRs) are the hypervariable regionspresent in heavy chain variable domains and light chain variabledomains. The CDRs of a heavy chain and the connected light chain of anantibody together form the antigen-binding site.

Now that the present invention provides the insight that the CDRsequences depicted in FIG. 2 provide desired binding characteristics, askilled person is well capable of generating variants comprising atleast, one altered CDR sequence. For instance, conservative amino acidsubstitution is applied. It is also possible to alter at least one CDRsequence depicted in FIG. 2 in order to generate a variant antibody, ora functional equivalent thereof, with at least one altered property ascompared to AM22. Preferably, an antibody or functional equivalent isprovided comprising a CDR sequence which is at least 70% identical to aCDR sequence as depicted in FIG. 2, so that the favorable bindingcharacteristics of AM22 are at least in part maintained or evenimproved. A CDR sequence as depicted in FIG. 2 is preferably alteredsuch that the resulting antibody or functional equivalent comprises atleast one improved property, such as for instance an improved stabilityand/or binding affinity, as compared to AM22. The binding specificity ispreferably maintained (in kind, not necessarily in amount). Variantantibodies or functional equivalents thereof comprising an amino acidsequence which is at least 70% identical to a CDR sequence as depictedin FIG. 2 are therefore also within the scope of the present invention.Various methods are available in the art for altering an amino acidsequence. For instance, a heavy chain or light, chain sequence with adesired CDR sequence is artificially synthesized. Preferably, a nucleicacid sequence encoding a CDR sequence is mutated, for instance usingrandom—or site-directed—mutagenesis.

Measurement of the affinity constant and specificity of binding betweenantigen and antibody is preferred in determining the efficacy ofprophylactic, therapeutic, diagnostic and research methods usinganti-RSV antibodies of the invention. “Binding affinity” generallyrefers to the strength of the sum total of the noncovalent interactionsbetween a single binding site of a molecule (e.g., an antibody) and itsbinding partner (e.g., an antigen). Unless indicated otherwise, as usedherein, “binding affinity” refers to intrinsic binding affinity whichreflects a 1:1 interaction between members of a binding pair (e.g.,antibody and antigen). The affinity can generally be represented by theequilibrium dissociation constant (Kd), which is calculated as the ratiok_(off)/k_(on). See, e.g., Chen, Y., et al., (1999) J. Mol Biol293:865-881. Affinity can be measured by common methods known in theart, such as for instance a surface plasmon resonance (SPR) assay suchas BiaCore or IBIS-iSPR instrument at IBIS Technologies BV (Hengelo, theNetherlands) or solution phase assays, such as Kinexa.

According to preferred embodiments, the present anti-RSV antibodies ofthe invention have binding affinities for an epitope on the RSV Fprotein that include a dissociation constant (K_(d)) of less than 1×10⁻²M, 1×10⁻³ M, 1×10⁻⁴ M, 1×10⁻⁵ M, 1×10⁻⁶ M, 1×10⁻⁷ M, 1×10⁻⁸ M, 1×10⁻⁹ M,1×10⁻¹⁰ M, 1×10⁻¹¹ M, 1×10⁻¹² M, 1×10⁻¹³ M, 1×10⁻¹⁴ M or less than1×10⁻¹⁵ M. In one embodiment, the anti-RSV antibodies have a K_(d) ofless than 10⁻⁷ M, less than 5×10⁻⁸ M, less than 10⁻⁸ M, less than 5×10⁻⁹M, less than 10⁻⁹ M, less than 5×10⁻¹⁰ M, less than 10⁻¹⁰ M, less than5×10⁻¹¹ M, less than 10⁻¹¹ M, less than 5×10⁻¹² M, less than 10⁻¹² M,less than 5×10⁻¹³ M, less than 10⁻¹³ M, less than 5×10⁻¹⁴ M, less than10⁻¹⁴ M, less than 5×10⁻¹⁵ M, or less than 10⁻¹⁵ M.

The invention further provides an isolated, synthetic or recombinantantibody or a functional part, derivative and/or analogue thereof, whichcomprises:

a heavy chain CDR1 sequence comprising a sequence which has at least 70%sequence identity to the sequence KLSIH (SEQ ID NO: 4), and/or

a heavy chain CDK2 sequence comprising a sequence which has at least 70%sequence identity to the sequence GYEGEVDEIFYAQKFQH (SEQ ID NO: 8),and/or

a heavy chain CDR3 sequence comprising a sequence which has at least 70%sequence identity to the sequence LGVTVTEAGLGIDDY (SEQ ID NO: 12) and/or

a light chain CDR1 sequence comprising a sequence which is at least 70%identical to the sequence RASQIVSRNHLA (SEQ ID NO: 20), and/or

a light chain CDR2 sequence comprising a sequence which is at least 70%identical to the sequence GASSRAT (SEQ ID NO: 24), and/or

a light chain CDR3 sequence comprising a sequence which is at least 70%identical to the sequence LSSDSSI (SEQ ID NO: 28).

Preferably, an antibody or functional equivalent according to theinvention comprises a CDR sequence which is at least 75%, morepreferably at least 80%, more preferably at least 85%, more preferablyat least 90% identical to at least one of the CDR sequences depicted inFIG. 2. Most preferably, an antibody or functional equivalent accordingto the invention comprises a CDR sequence which is at least 95%identical to at least one of the CDR sequences depicted in FIG. 2. Theparticularly preferred antibody AM22, described above, comprises CDRsequences which consist of the CDR sequences depicted in FIG. 2. Aparticularly preferred embodiment according to the invention thusprovides an isolated, synthetic or recombinant antibody or a functionalequivalent thereof which is capable of specifically binding RSV andwhich comprises:

a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), and/or

a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH(SEQ ID NO: 8), and/or

a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQID NO: 12), and/or

a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ IDNO: 20), and/or

a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and/or

a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28).

In one embodiment an antibody or functional equivalent is provided whichcomprises the heavy chain CDR1 and CDR2 sequences and the light chainCDR1 and CDR2 sequences as depicted in FIG. 2, or sequences that are atleast 70%, preferably at least 75%, more preferably at least 80%, morepreferably at least 85% identical thereto. Further provided is thereforean isolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof which comprises a heavy chain CDR1sequence comprising a sequence which is at least 70% identical to thesequence KLSIH (SEQ ID NO: 4) and a heavy chain CDR2 sequence comprisinga sequence which is at least 70% identical to the sequenceGYEGEVDEIFYAQKFQH (SEQ ID NO: 8) and a light chain CDR1 sequencecomprising a sequence which is at least 70% identical to the sequenceRASQIVSRNHLA (SEQ ID NO: 20) and a light chain CDR2 sequence comprisinga sequence which is at least 70% identical to the sequence GASSRAT (SEQID NO: 24). Said antibody or functional equivalent preferably comprisesCDR sequences which are at least 75%, more preferably at least 80%, morepreferably at least 85%, more preferably at least 90%, most preferablyat least 95% identical to the above mentioned heavy chain CDR sequencesand light chain CDR sequences. Preferably, said antibody or functionalequivalent also comprises a heavy chain CDR3 sequence comprising asequence which is at least 70% identical to the sequence LGVTVTEAGLGIDDY(SEQ ID NO: 12), and/or a light chain CDR3 sequence comprising asequence which is at least 70% identical to the sequence LSSDSSI (SEQ IDNO: 28). An antibody or functional equivalent comprising the abovementioned heavy chain CDR1, CDR2 and CDR3 sequences as well, as theabove mentioned light chain CDR1, CDR2 and CDR3 sequences is alsoprovided.

Optionally, said at least one human CDR sequence is optimized,preferably in order to improve binding efficacy or stability. This isfor instance done by mutagenesis experiments where after the stabilityand/or binding efficacy of the resulting compounds are preferably testedand an improved antibody or functional equivalent is selected.

Besides optimizing CDR sequences, it is often advantageous to optimizeat least one sequence in at least one of the frame work regions. This ispreferably done in order to improve binding efficacy or stability. Framework sequences are for instance optimized by mutating a nucleic acidmolecule encoding such frame work sequence where after thecharacteristics of the resulting antibody—or functional part—ispreferably tested. This way, it is possible to obtain improvedantibodies or functional parts. Isolated, synthetic or recombinantantibodies or functional parts, derivatives and/or analogues thereofcomprising a heavy chain amino acid sequence which has at least 70%sequence identity to the heavy chain sequence as depicted in FIG. 2 aretherefore also provided. Such heavy chain sequence provides desiredbinding properties, as evidenced by antibody AM22. Moreover, light chainamino acid sequences which have at Least 70% sequence identity to thelight chain sequence as depicted in FIG. 2 also provide desired bindingproperties, as evidenced by antibody AM22. Further provided is thereforean isolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof according to the invention, having aheavy chain sequence comprising a sequence which has at least 70%sequence identity to the sequenceQVQLVQSGAEVKKPGAIVKVSCKISGHTLIKXjSIHWVRQAPGKGLEWMGGYEGEVDEIFYAQKFQHRKLTVIADTATDTVYMELGKLTSDDTAVYFCGTLGVTVTEAGLGIDDYWGQGTLVTVSS (SEQ ID NO: 16) and/or having a light chainsequence which has at least 70% sequence identity to the sequenceEIVLTQSPGTLSLSPGERATLSCRASQIVSRNHLAWYQQKPGQAPRLLIFGASSRATGIPVRFSGSGSGTDFTLTINGLAPEDFAVYYCLSSDSSIFTFGPGTKV DFK (SEQ ID NO:32).

An isolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof according to the invention preferablycomprises a heavy chain sequence and/or a light chain sequence which isat least 75%, more preferably at least 80%, more preferably at least85%, more preferably at least 90%, most preferably at least 95%identical to a heavy chain sequence and/or a light chain sequence asdepicted in FIG. 2. The higher the homology, the more closely saidantibody or functional equivalent, resembles antibody AM22. An isolated,synthetic or recombinant antibody or a functional part, derivativeand/or analogue thereof according to the invention preferably comprisesa heavy chain as well as a light chain which resemble the heavy andlight chain of AM22. Further provided is therefore an isolated,synthetic or recombinant antibody or a functional part, derivativeand/or analogue thereof comprising a heavy chain sequence and a lightchain sequence which are at least 70%, more preferably at least 80%,more preferably at least 85%, more preferably at least 90%, mostpreferably at least 95% identical to the heavy chain sequence and thelight chain sequence, respectively, as depicted in FIG. 2. In oneembodiment ail antibody or functional equivalent is provided which has aheavy chain sequence as depicted in FIG. 2 and a light chain sequence asdepicted in FIG. 2.

One embodiment provides an isolated, synthetic or recombinant antibodyor a functional part, derivative and/or analogue thereof comprising aheavy chain sequence consisting of the heavy chain sequence as depictedin FIG. 2, and/or comprising a light chain sequence consisting of thelight chain sequence as depicted in FIG. 2. Alternatively, as is wellknown by the skilled person, it is possible to generate a shortenedheavy chain, or light chain sequence while maintaining a bindingproperty of interest. Preferably, such a shortened heavy chain or lightchain is generated which has a shorter constant region, as compared tothe original heavy or light chain. The variable domain is preferablymaintained. For instance, a Fab fragment or F(ab′)₂ fragment or a singledomain antibody or a single chain antibody or a nanobody or an unibodyor a scFv fragment based on a heavy chain sequence or light chainsequence depicted in FIG. 2 is produced. A functional part of anantibody comprising at least a functional part of a sequence as depictedin FIG. 2 is therefore also provided. Said functional part has a lengthof at least 20 amino acids and comprises at least one sequence selectedfrom the group consisting of a sequence which is at least 70% identicalto the heavy chain CDR1 sequence depicted in FIG. 2 and a sequence whichhas at least 70% sequence identity to the heavy chain CDR2 sequencedepicted in FIG. 2 and a sequence which has at least 70% sequenceidentity to the heavy chain CDR3 sequence depicted in FIG. 2 and asequence which has at least 70% sequence identity to the light chainCDR1 sequence depicted in FIG. 2 and a sequence which has at least 70%sequence identity to the light chain CDR2 sequence depicted in FIG. 2and a sequence which has at least 70% sequence identity to the lightchain CDR3 sequence depicted in FIG. 2.

As said before, antibodies and functional equivalents according to thepresent invention recognize a unique epitope of an RSV F protein trimer.Hence, antibodies and functional equivalents are provided thatspecifically recognize this epitope. Antibodies or functionalequivalents thereof that specifically recognize said unique epitope arepreferably combined with RSV-specific antibodies that are already known,such as palivizumab, D25, AM14, AM16 and AM23. By combining an antibodyor functional equivalent according to the invention that specificallyrecognizes said unique epitope with a known RSV-specific antibody, twoor more different epitopes of RSV are recognized during the sametherapy. This way, a stronger immunogenic response to RSV and/or ahigher antibody specificity against RSV is reached With a strongerimmunogenic response to and higher specificity against RSV, suchcombination will result in more effective treatment and/or prevention ofa RSV-related disorder.

Therefore, the invention provides an isolated, synthetic or recombinantantibody or a functional part, derivative and/or analogue thereof whichis capable of specifically binding an epitope that is recognized by anantibody which comprises:

a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), and/or

a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH(SEQ ID NO: 8), and/or

a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQID NO: 12), and/or

a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ IDNO: 20), and/or

a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and/or

a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28).

In a particularly preferred embodiment the invention provides anisolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof which is capable of specificallybinding an epitope that is recognized by an AM22 antibody whichcomprises:

a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), and

a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH(SEQ ID NO: 8), and

a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQID NO: 12), and

a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ IDNO: 20), and

a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and

a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28).

A further embodiment of the invention contemplates certain antibodyconstant region (Fc) modifications to alter effector functions. Forexample, the serum half-life of proteins comprising Fc regions isincreased by increasing the binding affinity of the Fc region for FcRn.The term “antibody half-life” as used herein means a pharmacokineticproperly of an antibody that is a measure of the mean survival time ofantibody molecules following their administration. Antibody half-lifecan be expressed as the time required to eliminate 50 percent of a knownquantity of immunoglobulin from the patient's body (or other mammal) ora specific compartment thereof, for example, as measured in serum, i.e.,circulating half-life, or in other tissues. Half-life may vary from oneimmunoglobulin or class of immunoglobulin to another. In general, anincrease in antibody half-life results in an increase in mean residencetime (MRT) in circulation for the antibody administered.

The increase in half-life allows for the reduction in amount of druggiven to a patient as well as reducing the frequency of administration.To increase the serum half life of an antibody according to theinvention, one may incorporate a salvage receptor binding epitope intothe antibody (especially an antibody fragment) as described in U.S. Pat.No. 5,739,277, for example. As used herein, the term “salvage receptorbinding epitope” refers to an epitope of the Fc region of an IgGmolecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsible forincreasing the in vivo serum half-life of the IgG molecule.Alternatively, antibodies of the invention with increased half-lives maybe generated by modifying amino acid residues identified as involved inthe interaction between the Fc and an FcRn receptor (see, for examples,U.S. Pat. Nos. 6,321,505 and 7,083,784). In addition, the half-life ofantibodies of the invention may be increased by conjugation to PEG orAlbumin by techniques widely utilized in the art. In some embodimentsantibodies comprising Fc variant regions of the invention have anincreased half-life of about 5%, about 10%, about 15%, about 20%, about25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%,about 65%, about 70%, about 80%, about 85%, about 90%, about 95%, about100%, about 125%, about 150% or more as compared to an antibodycomprising a native Fc region. In some embodiments antibodies comprisingFc variant regions have an increased half-life of about 2 fold, about 3fold, about 4 fold, about 5 fold, about 10 fold, about 20 fold, about 50fold or more, or is between 2 fold and 10 fold, or between 5 fold and 25fold, or between 15 fold and 50 fold, as compared to an antibodycomprising a native Fc region. The invention therefore provides anantibody, functional part, derivative or analogue according theinvention, comprising a salvage receptor binding epitope, and/ormodified amino add residues identified as involved in the interactionbetween the Fc and an FcRN receptor, and/or non naturally occurringamino acid residues. Another preferred embodiment provides an antibodyor functional equivalent according to the invention which is conjugatedto PEG or Albumin.

In one embodiment, the present invention provides Fc variants accordingto the invention, wherein the Fc region comprises a modification (e.g.,amino acid substitution, amino acid insertion, amino acid deletion) atone or more positions selected from the group consisting of 234, 235,236, 237, 238, 239, 240, 241, 243, 244, 245, 247, 251, 252, 254, 250,256, 262, 263, 264, 265, 266, 267, 268, 269, 279, 280, 284, 292, 296,297, 298, 299, 305, 313, 316, 325, 326, 827, 328, 329, 330, 331, 332,333, 334, 339, 341, 343, 370, 373, 378, 392, 416, 419, 421, 440 and 443as numbered by the EU index as set forth in Kabat et al (J Immunol.1991; 147(5): 1709-19). Optionally, the Fc region comprises a nonnaturally occurring amino acid residue at additional and/or alternativepositions known to one skilled in the art (see. e.g., U.S. Pat. Nos.5,624,821; 6,277,375; 6,737,056; 7,083,784; 7,317,091; 7,217,797;7,276,585; 7,355,008; 2002/0147311; 2004/0002587; 2005/0215768;2007/0135620; 2007/0224188; 2008/0089892; WO 94/29351; and WO 99/58572).

In a specific embodiment, the present invention provides an Fc variantantibody according to the invention, wherein the Fc region comprises atleast one non-naturally occurring amino acid at one or more positionsselected from the group consisting of 252, 254, and 256. In oneembodiment, the non-naturally occurring amino acids are selected fromthe group consisting of 252Y, 254T and 256E.

The present invention provides RSV-specific antibodies and functionalequivalents thereof having improved properties as compared to prior artantibodies. The inventors have succeeded in generating RSV-specificantibodies with the lowest IC₅₀ value currently known. Such antibodieshave a particular high or strong affinity for RSV and are thereforeparticularly suitable for counteracting and/or at least in partpreventing an RSV-infection and/or adverse effects of an RSV infection.One embodiment therefore provides an antibody which has an IC₅₀ value ofless than 1.25 ng/ml, preferably less than 1.2 ng/mL, more preferablyless that 0.1.19 ng/ml, more preferably less than 1.18 ng/ml, and mostpreferably between 1.1 ng/ml and 1.17 as determined in the in vitroneutralization assay described in the examples (see FIG. 1).

The invention further provides an isolated, synthetic or recombinantnucleic, acid sequence or a functional equivalent thereof with a lengthof at least 15 nucleotides, preferably at least 30 nucleotides, morepreferably at least 60 nucleotides, more preferably at least 75nucleotides, encoding at least an antigen-binding part of an antibody orfunctional equivalent according to the invention. Such nucleic acid isfor instance isolated from a B-cell which is capable of producing anantibody according to the invention. A preferred embodiment provides anucleic acid sequence comprising a sequence which has at least 70%sequence identity to at least 15 nucleotides of a nucleic acid sequenceas depicted in FIG. 2. A nucleic acid sequence according to theinvention preferably comprises a sequence which has at least 75%, morepreferably at least 80%, more preferably at least 85%, more preferablyat least 90%, most preferably at least 95% sequence identity to at least15 nucleotides of a nucleic acid sequence as depicted in FIG. 2.Preferably, said nucleic acid sequence as depicted in FIG. 2 comprisesat least one CDR encoding sequence.

One preferred embodiment provides an isolated, synthetic or recombinantnucleic acid sequence with a length of at least 15 nucleotides, or afunctional equivalent thereof, encoding at least one CDR sequence of anantibody or functional equivalent according to the invention. Saidnucleic acid sequence preferably encodes at least one CDR sequence whichhas at least 70% sequence identity to a CDR region of antibody AM22.Nucleic acid sequences encoding AM22 CDR regions are depicted in FIG. 2.Further provided is therefore an isolated, synthetic or recombinantnucleic acid sequence, or a functional equivalent thereof, comprising asequence which has at least 70% sequence identity to a sequence selectedfrom the group consisting of aaattatccatteac (SEQ ID NO: 3),ggttatgagggtgaggtcgatgagattttctacgcacagaagttccagcac (SEQ ID NO: 7),ctaggtgtgacagtgactgaggctggactggggatcgatgactac (SEQ ID NO: 11),agggccagtcagattgttagcaggaaccacttagcc (SEQ ID NO: 19),ggtgcgtccagtcgggccact (SEQ ID NO: 23) and ctgtcctctgattcctccata (SEQ IDNO: 27).

Said nucleic acid sequence or functional equivalent preferably comprisesa sequence which has at least 75%, more preferably at least 80%, morepreferably at least 85%, more preferably at least 90% sequence identityto any of the above mentioned nucleic acid sequences. Further providedis a nucleic acid sequence or functional equivalent thereof comprising asequence which has at least 70% sequence identity to at least part of anucleotide sequence as depicted in FIG. 2, said part having at least 15nucleotides and encoding at least one CDR region as depicted in FIG. 2.

A nucleic acid sequence or functional equivalent thereof according tothe present invention preferably encodes a region which has at least 70%sequence identity to an AM22 CDR region, an AM22 heavy chain and/or anAM22 light chain. One embodiment thus provides an isolated, synthetic orrecombinant nucleic acid sequence, or a functional equivalent, thereof,comprising a sequence encoding an amino acid sequence which has at least70% sequence identity to the sequence KLSIH (SEQ ID NO: 4), and/or atleast 70% sequence identity to the sequence GYEGEVDEIFYAQKFQH (SEQ IDNO: 8), and/or at least 70% sequence identity to the sequenceLGVTVTEAGLGIDDY (SEQ ID NO: 12), and/or at least 70% sequence identityto the sequence RASQIVSRNHLA (SEQ ID NO: 20), and/or at least 70%sequence identity to the sequence GASSRAT (SEQ ID NO: 24), and/or atleast 70% sequence identity to the sequence LSSDSSI (SEQ ID NO: 28),and/or at least 70% sequence identity to the sequenceQVQLVQSGAEVKKPGATVKVSCKISGHTLIKLSIHWVRQAPGKGLEWMGGYEGEVDEIFYAQKFQHRLTVIADTATDTVYMELGRLTSDDTAVYFCGTLGVTVTEAGLGIDDYWGQGTLVTVSS (SEQ ID NO: 16), and/or at least 70% sequenceidentity to the sequenceEIVLTQSPGTLSLSPGERATLSCRASQIVSRNHLAWYQQKPGQAPRLLIFGASSRATGIPVRFSGSGSGTDFTLTINGLAPEDFAVYYCLSSDSSIFTFGPGTKV DFK (SEQ ID NO:32).

As said before, an antibody or functional equivalent according to theinvention is capable of recognizing a unique epitope present on trimericRSV F proteins. A nucleic acid sequence according to the invention thuspreferably encodes a CDR sequence capable of specifically binding thisunique epitope. Also provided by the invention is therefore an isolated,synthetic or recombinant nucleic acid sequence or a functionalequivalent thereof, encoding at least one CDR sequence capable ofspecifically binding an epitope that is recognized by an antibody whichcomprises:

a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), and/or

a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH(SEQ ID NO: 8), and/or

a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQID NO: 12), and/or

a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ IDNO: 20), and/or

a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and/or

a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28).

Preferably, said nucleic acid sequence encodes a whole antibody orfunctional equivalent (for instance comprising a heavy chain or lightchain) according to the invention. Further provided is therefore anisolated, synthetic or recombinant nucleic acid sequence, or afunctional equivalent thereof, encoding an antibody or functionalequivalent thereof capable of specifically binding an epitope that isrecognized by an antibody which comprises:

a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), and/or

a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH(SEQ ID NO: 8), and/or

a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQID NO: 12), and/or

a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ IDNO: 20), and/or

a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and/or

a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28).

In one embodiment of the invention a nucleic acid sequence or functionalequivalent encodes an antibody or a functional part, derivative and/oranalogue thereof capable of specifically binding an epitope that isrecognized by an AM22 antibody, which comprises a heavy chain CDR Lsequence comprising the sequence KLSIH (SEQ ID NO: 4), and a heavy chainCDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH (SEQ II) NO: 8),and a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY(SEQ ID NO: 12), and a light chain CDR1 sequence comprising the sequenceRASQIVSRNHLA (SEQ ID NO: 20), and a light chain CDR2 sequence comprisingthe sequence GASSRAT (SEQ ID NO: 24), and a light chain CDR3 sequencecomprising the sequence LSSDSSI (SEQ ID NO: 28).

A nucleic acid sequence or functional equivalent, according to theinvention preferably encodes an antibody or functional equivalentthereof that has a dissociation constant (K_(d)) of less than 1×10⁻² M,1×10⁻³ M, 1×10⁻⁴ M, 1×10⁻⁵ M, 1×10⁻⁶ M, 1×10⁻⁷ M, 1×10⁻⁸ M, 1×10⁻⁹ M,1×10⁻¹⁰ M, 1×10⁻¹¹ M, 1×10⁻¹² M, 1×10⁻¹³ M, 1×10⁻¹⁴ M or less than1×10⁻¹⁵ M.

Further provided is a vector comprising a nucleic acid sequenceaccording to the invention. Such vector is suitable for a variety ofapplications. For instance, a vector of the invention comprising atherapeutically beneficial nucleic acid sequence is suitable forprophylactic or therapeutic applications. Administration of such vectorto an individual in need thereof results in expression of saidprophylactic or therapeutic nucleic acid sequence in vivo. Said vectorcan also be used in applications involving in vitro expression of anucleic acid sequence of interest, for instance for (commercial)production of antibodies or functional equivalents according to theinvention. Methods for constructing a vector with a nucleic acidsequence according to the invention are well known in the art.Non-limiting examples of vectors suitable for generating a vector of theinvention are retroviral and lentiviral vectors.

The term “% sequence identity” is defined herein as the percentage ofresidues in a candidate amino acid sequence or candidate nucleic acidsequence that is identical with the residues in a reference sequenceafter aligning the two sequences and introducing gaps, if necessary, toachieve the maximum percent identity. Methods and computer programs forthe alignment are well known in the art.

As used herein, a nucleic acid molecule or nucleic acid sequence of theinvention preferably comprises a chain of nucleotides, more preferablyDNA and/or RNA. In other embodiments a nucleic acid molecule or nucleicacid sequence of the invention comprises other kinds of nucleic acidstructures such as for instance a DNA/RNA helix, peptide nucleic acid(PNA), locked nucleic acid (LNA) and/or a ribozyme. Such other nucleicacid structures are referred to as functional equivalents of a nucleicacid sequence. The term “functional equivalent of a nucleic acidsequence” also encompasses a chain comprising non-natural nucleotides,modified nucleotides and/or non-nucleotide building blocks which exhibitthe same function as natural nucleotides.

A nucleic acid sequence or vector according to the present invention isparticularly useful, for generating antibodies or functional equivalentswhich are specific for RSV. This is for instance done by introducingsuch nucleic acid sequence or vector into a cell so that the cell'snucleic acid translation machinery will produce the encoded antibody orfunctional equivalent. In one embodiment, a nucleic acid sequence orvector encoding a heavy and/or light chain according to the invention isexpressed in so called producer cells, such as for instance cells of aChinese hamster ovary (CHO), NSO (a mouse myeloma) or 293(T) cell line,some of which are adapted to commercial antibody production.Proliferation of said producer cells results in a producer cell linecapable of producing antibodies or functional equivalents thereofaccording to the present invention. Preferably, said producer cell lineis suitable for producing antibodies for use in humans. Hence, saidproducer cell line is preferably free of pathogenic agents such aspathogenic micro-organisms. Most preferably, antibodies or functionalequivalents consisting of human sequences are generated using at leastone nucleic acid sequence or vector according to the invention.

An isolated or recombinant antibody producing cell capable of producingan antibody or a functional part, derivative and/or analogue thereofaccording to the invention is therefore also provided, as well as amethod for producing an isolated, synthetic or recombinant antibody orfunctional part, derivative and/or analogue according to the invention,comprising providing a cell with a nucleic acid sequence or functionalequivalent or vector according to the invention and allowing said cellto translate said nucleic acid sequence or functional equivalent orvector, thereby producing said antibody or functional part, derivativeand/or analogue thereof.

An antibody producing cell is defined herein as a cell which is capableof producing and/or secreting antibody or a functional equivalent,thereof, and/or which is capable of developing into a cell which iscapable of producing and/or secreting antibody or a functionalequivalent thereof. An antibody producing cell according to theinvention is preferably a producer cell which is adapted to commercialantibody production. Preferably, said producer cell is suitable forproducing antibodies for use in humans.

A method according to the invention preferably further comprises a stepof harvesting, purifying and/or isolating said antibody or functionalpart, derivative and/or analogue thereof according to the invention.Obtained antibodies or functional equivalents according to the inventionare preferably used in human therapy, optionally after additional,purifying, isolation or processing steps.

Now that improved Respiratory Syncytial Virus-specific antibodies orfunctional equivalents according to the invention and nucleic acidsequences and vectors coding therefore have been provided, includinghuman antibodies or functional equivalents, improved prophylactic and/ortherapeutic applications have become available. RSV is counteracted byantibodies or functional equivalents according to the invention. Anantibody or functional equivalent according to the invention istherefore particularly suitable for use as a medicine or prophylacticagent, optionally in combination with at least one other RSV-specificantibody known in the art. Preferably, antibodies or functionalequivalents are used which consist of human sequences, or which have atmost 5% of non-human sequences, in order to reduce the chance of adverseside effects when human individuals are treated. An isolated, syntheticor recombinant antibody or a functional part, derivative and/or analoguethereof or a nucleic acid sequence or functional equivalent thereof or avector or a cell according to the invention for use as a medicamentand/or prophylactic agent is therefore also herewith provided. When anucleic acid or functional equivalent or vector according to theinvention is administered, it will be translated in situ into anantibody or functional equivalent according to the invention. In aparticularly preferred embodiment said antibody comprises antibody AM22,or a functional equivalent thereof. Said medicament or prophylacticagent is preferably used for counteracting or at least in partpreventing an infection by RSV. Further provided is therefore anisolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof or a nucleic acid sequence orfunctional equivalent thereof or vector or cell according to theinvention for use as a medicament and/or prophylactic agent for at leastin part treating and/or preventing a disorder related to RSV. Amedicament that comprises AM22 in combination with at least one otherRSV-specific agent, preferably an antibody, known in the art, isparticularly advantageous because with such combination a strongerimmunogenic response to RSV is obtained and/or higher antibodyspecificity against RSV is reached. Further provided is therefore acombination of an isolated, synthetic or recombinant antibody or afunctional part, derivative and/or analogue thereof or a nucleic acidsequence or functional equivalent thereof or vector or cell according tothe invention and another, different RSV-specific agent, preferably anantibody or functional equivalent thereof, for use as a medicamentand/or prophylactic agent. A combination according to the inventionpreferably comprises AM22 and an antibody selected from the groupconsisting of palivizumab, D25, AM14, AM16 and AM23. As said before,such combination is particularly suitable for at least in part treatingor preventing a RSV-related disorder. Further provided is therefore ause of a combination according to the invention for the preparation of amedicament and/or prophylactic agent, for at least in part treatingand/or preventing a disorder related to RSV. A use of an isolated,synthetic or recombinant antibody or a functional part, derivativeand/or analogue thereof or a nucleic acid sequence or functionalequivalent thereof or vector or cell according to the invention for thepreparation of a medicament and/or prophylactic agent for at least inpart treating and/or preventing an RSV-related disorder is thereforealso provided, as well as a method for at least in part treating orpreventing a RSV-related disorder, the method comprising administeringto an individual in need thereof a therapeutically effective amount, ofan isolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof according to the invention. In onepreferred embodiment, a combination with at least one other RSV-specificagent, preferable another RSV specific antibody, is used. Saidindividual has preferably been diagnosed to be infected by RSV beforetreatment.

Said antibody preferably comprises antibody AM22, or a functional partthereof. Said at least one other RSV-specific antibody is preferablypalivizumab. D25, AM14, AM16 or AM23. Moat preferably a combination ofAM22 and D25 is used.

In order to at least in part treat or prevent a disorder related toRespiratory Syncytial Virus, an antibody or functional equivalentaccording to the invention is preferably administered to an individualbefore an infection has taken place. Alternatively, an antibody orfunctional equivalent according to the invention is administered when anindividual is already infected. Said antibody or functional equivalentis preferably administered to individuals with an increased risk ofcomplications, such as for instance hospitalized individuals and/orindividuals with compromised immunity. Also elderly people have anincreased risk of RSV infection. Antibodies or functional equivalentsaccording to the invention are preferably administered via one or moreinjections. Dose ranges of antibodies or functional equivalentsaccording to the invention to be used in the prophylactic or therapeuticapplications as described herein before are designed on the basis ofrising dose studies in the clinic in clinical trials for which rigorousprotocol requirements exist. Typical doses are between 0.1 and 10 mg perkg body weight. For prophylactic or therapeutic application antibodiesor functional equivalents according to the invention are typicallycombined with a pharmaceutically acceptable carrier, diluent and/orexcipient. Examples of suitable carriers for instance comprise keyholelimpet haemocyanin (KLH), serum albumin (e.g. BSA or RSA) and ovalbumin.In one preferred embodiment said suitable carrier comprises a solutionlike for example saline.

In yet another embodiment a nucleic acid or a vector encoding anantibody or functional equivalent according to the invention is used. Asalready described, upon administration of such nucleic acid or vector,antibodies or functional equivalents are produced by the host'smachinery. Produced antibodies or functional equivalents are capable ofat least in part preventing and/or counteracting Respiratory SyncytialVirus infection and/or the adverse effects of such infection. A nucleicacid sequence or functional equivalent or a vector according to theinvention for use as a medicament a rid/or prophylactic agent istherefore also herewith provided. Further provided is a use of a nucleicacid sequence or functional equivalent or vector according to theinvention for the preparation of a medicament and/or prophylactic agentfor at least in part, treating and/or preventing a RSV-related disorder.

Further provided is a pharmaceutical composition comprising an isolated,synthetic or recombinant antibody or a functional part, derivativeand/or analogue thereof or a nucleic acid sequence or functionalequivalent thereof or vector or cell according to the invention and apharmaceutical acceptable carrier, diluent or excipient. Saidpharmaceutical composition is preferably suitable for human use. In onepreferred embodiment said antibody is AM22. In a further preferredembodiment said nucleic acid encodes AM22 or a functional equivalentthereof. In one embodiment said pharmaceutical composition furthercomprises at least one other RSV-specific antibody, preferablypalivizumab, D25, AM14, AM16 and/or AM23.

The invention is further explained in the following examples. Theseexamples do not limit the scope of the invention, but merely serve toclarify the invention.

REFERENCES

-   Chen Y, Wiesmann C, Fuh G, Li B, Christinger H W, McKay P, de Vos A    M, Lowman H B. Selection and analysis of an optimised anti-VEGF    antibody: crystal structure of an affinity-matured Fab in complex    with antigen. J Mol Biol. 1999; 293(4):865-81.-   Diehl S A, Schmidlin H, Nagasawa M, van Haren S D, Kwakkenbos M J,    Yasucla E, Beaumont T, Scheeren F A. Spits H. STAT3-mediated    up-regulation of BLUMP1 Is coordinated with BCL6 down-regulation to    control human plasma cell differentiation. J Immunol. 2008;    180(7):4805-15.-   Jaleco A C, Stegmann A P, Heemskerk M H, Couwenberg F, Bakker A Q,    Weijer K, Spits H. Genetic modification of human B-cell development:    B-cell development is inhibited by the dominant negative helix loop    helix factor Id3. Blood. 1999; 94(8):2687-46.-   Kabat E A, Wu T T. Identical V region amino acid sequences and    segments of sequences in antibodies of different specificities.    Relative contributions of VH and VL genes, minigenes, and    complementarity-determining regions to binding of antibody-combining    sites. J Immunol. 1991: 147(5): 1709-19.-   Kwakkenbos M J, Diehl S A, Yasuda E, Bakker A Q, Van Geelen C M M,    Lukens M V, Van Bleek G M, Widjojoatmodjo M N, Bogers W M J M, Mei    H, Radbruch A, Scheeren F A, Spits H and Beaumont T. Generation of    stable monoclonal antibody-producing BCR⁺ human memory B cells by    genetic programming. Nat Med. 2009 In press.-   Shvarts A, Brummelkamp T R, Scheeren F, Koh E, Daley G Q, Spits H,    Bernards R. A senescence rescue screen identifies BCL6 as an    inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev.    2002; 16(6):681-6.-   Scheeren F A, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands    E, Gimeno R, Vyth-Dreese F A, Blom B, Spits H. STAT5 regulates the    self-renewal capacity and differentiation of human memory B cells    and controls Bcl-6 expression, Nat Immunol. 2005; 6(3):303-13.-   Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity and    efficacy of codon optimized DNA vaccines encoding the F-protein of    respiratory syncytial virus. Vaccine. 2007: 25(41):7271-9.-   U.S. Pat. No. 5,624,821-   U.S. Pat. No. 5,739,277-   U.S. Pat. No. 6,277,375-   U.S. Pat. No. 6,737,056-   U.S. Pat. No. 6,821,505-   U.S. Pat. No. 7,083,784-   U.S. Pat. No. 7,317,091-   U.S. Pat. No. 7,217,797-   U.S. Pat. No. 7,276,585-   U.S. Pat. No. 7,355,008-   US 2002/0147311-   US 2004/0002587-   US 2005/0215768-   US 2007/0135620-   US 2007/0224188-   US 2008/0089892-   WO 94/2935.1-   WO 99/58572-   WO 2008/147196

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. AM22, a novel fully human monoclonal antibody, neutralizes theRSV A2 virus very efficiently on Hep2 cells compared to palivizumab.

FIGS. 2A and 2B. FIG. 2A shows AM22 heavy chain nucleotide sequences andamino acid sequences. FIG. 2B shows light chain nucleotide sequences andamino acid sequences.

FIGS. 3A-3D. Human anti-RSV monoclonal antibodies recognizeconformational epitopes on the Fusion (F) protein of RSV as determinedby ELISA and FACS staining. FIG. 3A shows binding of the antibodies toEL-4 cells infected with Vesicular Stomatitis Virus (VSV) which waspseudotyped with the RSV F or RSV G protein. FIG. 3B shows binding ofthe anti-RSV F antibodies to ELISA plates that were coated with a lysateof RSV infected HEp2 (left panel) or with Ni-NTA HisSorp Plates (Qiagen)coated with recombinant HIS tagged F protein (right panel). Antibodybinding to the F protein is detected with HRP-conjugated IgG detectionantibody (dilutions 1:2500, Jackson). FIG. 3C shows binding of therecombinant RSV F Long strain containing a poly HIS tag to the originalB cell clones, binding to the BCR is detected with an anti-pentaHISantibody. FIG. 3D shows the intracellular binding of the human anti-RSVantibodies to 293T cells transfected with a recombinant RSV F constructcontaining a trimerization domain (ILZ domain).

FIGS. 4A-4C. RSV challenge in Cotton rats prophylactically treated withhuman immunoglobulins. FIG. 4A shows the retrieval of human IgG1 fromserum at day 1 and day 5 after intramuscular administration of indicateddoses of antibodies in Cotton rats. FIG. 4B shows the RSV load in thelungs of Cotton rats treated with the indicated antibodies 24 hoursbefore infection with RSV-X. RSV load was determined 5 days afterinfection with TCID₅₀ culture. Experiments were performed twice withfour to six individual animals per treatment group. Lung pathology wasstudied in the same animal groups (FIG. 4C), indicated is the averagelung pathology of AM22 and palivizumab, see also table 2.

EXAMPLES Example 1. B Cell Culture, Immortalization and SelectionMethods

B cells were immortalized and cultured as described before (Scheeren FA, et al. (2005) Nat Immunol 6: 303-313; Diehl S A, et al. (2008) JImmunol 180: 4805-4815 and Kwakkenbos M J, et al. (2009) Nat Med inpress). In brief we isolated B cells from peripheral blood (Sanquin,Amsterdam, The Netherlands) by Ficoll separation, CD22 MACS microbeads(Miltenyi Biotech) and subsequently cell sorting forCD19⁺CD3⁻CD27⁺IgM⁻IgA⁻ (IgG memory cells) on a FACSAria (BectonDickinson). The use of these tissues was approved by the medical ethicalcommittees of the institution and was contingent on informed consent.Retroviral transduced B cells, were maintained at 2×10⁵ cells ml⁻¹ inIMDM supplemented with recombinant mouse IL-21 (25 ng ml⁻¹, R&D systems)and co-cultured with γ-irradiated (50Gy) mouse L cell fibroblasts stablyexpressing CD40L (CD40L-L cells, 10⁵ cells ml⁻¹) for 30 hours. The BCL6and Bcl-xL retroviral constructs were described previously (Shvarts A,et al. (2002) Genes Dev 16: 681-686 and Jaleco A C, et al. (1999) Blood94: 2637-2646)) and were cloned into the LZRS retroviral vector andtransfected in Phoenix packaging cells as described before and added tothe stimulated B cells (Shvarts A, et al (2002) Genes Dev 16; 681-686and Scheeren F A, et al. (2005) Nat Immunol 6: 303-313). Transduced Bcells were maintained in IMDM, in the presence of recombinant IL-21 andCD40L-L cells for prolonged periods of time. Given the relatively highamounts of secreted antibodies by BCL6+Bcl-xL transduced B cells weexamined whether we could select antigen-specific B cells on the basisof secretion of specific antibody. BCL6+Bcl-xL transduced memory B cellsof a healthy donor were seeded at 100 cells/well and expanded withCD40L-L cells and IL-21. After 2 weeks of culture, supernatants wereharvested and screened for the presence of RSV-neutralizing antibodiesin a microneutralization experiment. Of 384 cultures (100 cell s/well),31 prevented RSV A2 infection, of HEp2 cells. Besides the fourmicrocultures from which D25, AM14, AM16, and AM23 were subcloned bylimiting dilution, we next obtained AM22. AM22 has a median half maximuminhibitory concentrations (IC₅₀) against the RSV-A2 virus of 1.15 ngml⁻¹ (FIG. 1).

To obtain the sequence of the heavy and Light, chain of theimmunoglobulin locus of AM22, we isolated total RNA with the RNeasy®mini kit (Qiagen), generated cDNA, performed PCR and cloned the heavyand light chain variable regions into the pCR2.1 TA cloning vector(Invitrogen), To rule out reverse transcriptase or DNA polymeraseinduced mutations, we performed several independent cloning experiments.To produce recombinant AM22 mAb we cloned AM22 heavy and light variableregions in frame with human IgG1 and Kappa constant regions into apcDNA3.1 (Invitrogen) based vector and transiently transfected 293Tcells. We purified recombinant AM22 from the culture supernatant withProtein A.

Results

Previously we developed four potent, conformational dependent anti-RSVantibodies, named AM14, AM16, AM23 and D25. These antibodies have beendescribed in WO 2008/147196 and by Kwakkenbos M J et al. (2009) Nat Medin press. From the same donor we also discovered AM22, which recognizedthe RSV virus even more efficiently compared to the other antibodies asis evident from an IC₅₀ of 1.15 ng ml⁻¹ against the RSV A2 virus (table1 and FIG. 1). The amino acid sequence of the VH and VL chain of AM22revealed that this antibody is different from the other antibodies (FIG.2).

Example 2. In Vitro Binding Experiments

To further determine the antigen specificity of the AM22 antibody weperformed in vitro binding experiments to reveal whether the proteinrecognized the RSV F or G protein and in what type of conformation.

Methods (1) FACS Staining of RSV G or F Protein

Virus stock of wild type and recombinant Vesicular Stomatitis Virus(VSV) expressing RSV-G protein (VSV-G) or RSV-F protein (VSV-F)(experiments were performed by M. Lukens at WKZ, Utrecht and VSV viruseswere kindly provided by J. S. Kahn and J. K Rose, Yale UniversitySchool, of Medicine) were prepared on BHK cells grown in DMEM containing5% FCS, penicillin/streptomycin and 50 μM 2-mercapto-ethanol. VSVinfection was performed on EL-4 cells that were cultured in Iscove'sModified Dulbecco's medium (IMDM, Gibco. Invitrogen) supplemented with5% FCS, penicillin/streptomycin and 50 μM 2-mercapto-ethanol. EL-4 cellsinfected with the VSV virus variants were incubated with recombinantantibody and subsequently stained with mouse-anti-human PE (FIG. 3A).

(2) RSV ELISA

Plates were coated with lysate of RSV infected HEp-2 cells in PBS for 1hour at 37° C. or o/n at 4° C. and washed in ELISA wash buffer (PBS,0.5% Tween-20). Plates were blocked by incubation with 4% milk in PBS,before the anti RSV antibodies or polyclonal goat anti-RSV (Biodesign)in combination with enzyme-conjugated anti-IgG antibodies were added(dilutions 1:2500 for HRP-conjugated anti-IgG (Jackson). TMBsubstrate/stop solution (Biosource) was used for development of theELISAs (FIG. 3B left panel). In addition to the lysate of RSV-A2infected HEp-2 cells, HIS-tagged F protein from RSV Long strain (kindlyprovided by Frank Coenjaerts, UMCU, Utrecht based on Ternette N, et al.(2007) Vaccine 25: 7271-7279) was used to coat Ni-NTA HisSorp Plates(Qiagen) (FIG. 3B right panel). The binding of the RSV F antibodies wasdetected with MRP-conjugated IgG detection antibody (dilutions 1:2500,Jackson). In another setting the original B cell clones were used forFACS analysis (FIG. 3C). The B cells were incubated with the recombinantHIS tagged F protein and binding to the BCR was detected with a labeledanti-penta HIS antibody ALEXA fluor 647 (Qiagen).

(3) RSV Trimers

In addition to the recombinant RSV long strain derived F protein wecreated RSV A2 F trimers by inserting the open reading frame of F into aconstruct, which is fused to an isoleucine zipper domain followed by 8HIS repeats (ILZ-8×HIS), Protein constructs were transiently expressedin 293T cells and detected by using an intracellular staining protocolusing the Fix Perm kit of BD (FIG. 3D).

Results

All antibodies recognized the RSV-F protein when expressed byrecombinant VSV (FIG. 3A). Furthermore, except for AM16, recognition wasdependent on the presence of conformational epitopes in the RSV-Fprotein since they did not recognize a lysate of RSV infected HEp-2cells (FIG. 3B left panel). Also purified HIS-tagged recombinant RSV-FLong strain protein was not recognized by D25, AM14, AM22 and AM23 whentested in a direct ELISA (FIG. 3B right panel). However when theoriginal stable BCR expressing B cell lines were incubated with thisnon-purified culture supernatant of the HIS tagged RSV-F protein we didobserve binding to the B cell clones AM16, AM23 and less strong to D25(FIG. 3C). The protein in this non purified culture supernatant possiblycontains a fraction of RSV F trimers that do bind the BCR but are onlycaptured as monomers on the HisSorp Plates. However still no RSV-Fprotein capture was observed to the BCRs of the AM14 and the AM22 B celllines (FIG. 3C). Thus AMU and AM22 bind to different epitopes. Possiblya low percentage of protein F homotrimers or dimers was present in theuntreated culture supernatant of the F protein producing cell line.These more native F conformations may express the epitopes recognized byAM23 and D25, which were lost in the denaturizing conditions of theELISA procedures. Interestingly when we performed an intracellularstaining on 293T cells transfected with the RSV trimerization constructcontaining the ILZ-8×HIS sequence we found that, AM22 did recognize RSVF (FIG. 3D), however AM14 still did not recognize this proteinstructure. Thus AM22 is unique since it recognizes a conformation of theRSV-F protein that is not present in denaturing conditions and thus isnot present in the monomeric form of the protein. Only when the RSV Fproteins are forced to stay together and form trimers then we can detectF binding by the AM22 antibody, a conformation that is present on virusparticles and thus explain the high neutralizing potency of AM22.

Example 3. In Vivo Potency Experiments

To study the in vivo potency of the AM22 monoclonal antibody weperformed Cotton rat experiments.

Methods

Pathogen free 7-9 week-old Cotton rats (Sigmodon hispidus, HarlanLaboratories, Nederland) were anesthetized with isoflurane and given 0.1ml of purified antibody by intramuscular (i.m.) injection at doses of2.0 or 0.4 mg kg⁻¹ for the control antibody, palivizuinab, AM22, AM23and D25, while AM14 was administered at 0.4 and 0.1 mg kg⁻¹. Twenty-fourhours later, animals were anesthetized, bled for serum hIgGdetermination and challenged by intranasal instillation of 10⁶ TCID₅₀RSV-X (100 μl). Five days later animals were sacrificed and their lungswere harvested. Lung virus titers were determined and the lowest limitof detection was 2.1 log₁₀ TCID₅₀ g⁻¹. The Animal Experiment Committeeof the Netherlands Vaccine Institute approved all procedures involvingCotton rats.

Results

The anti-RSV antibody panel, except AM16, was tested in Cotton rats.Animals were prophylactically treated with 2.0 or 0.4 mg kg⁻¹ ofmonoclonal antibodies before RSV-X, a primary RSV A isolate, wasintra-nasally administered. Due to relatively low antibody production,the AM14 antibody was administered at 0.4 and 0.1 mg kg⁻¹. The level ofrecovered human IgG from Cotton rat sera at day 1 (day of virusinoculation) and day 5 (day of sacrifice) was in the same range for allantibodies and the decline of antibodies in time was comparable (FIG.4A).

The retrieval of RSV virus from the lungs of sacrificed animals wasstrongly reduced in all animal groups treated with 2.0 mg/kg ofimmunoglobulin compared to the control group (FIG. 4B). Animals treatedwith 0.4 mg kg⁻¹ palivizumab and AM23 showed significant virusreplication, while in the AM14 and D25 groups one out of 6 animalsshowed detectable virus replication. No virus could be retrieved fromanimals treated with AM22. These results demonstrate that AM22, thatspecifically recognized conformational epitopes on the RSV F protein,harbors strong in vivo neutralizing capacities.

Analysis of Lung Pathology of RSV Challenged Cotton Rats

From each Cotton rat at day 5 after i.n. RSV infection the left lung wasremoved and fixed with formalin. Lung damage was classified between 0-6for three individual markers: 1) hypertrophy of bronchus and bronchioliepithelia, 2) inflammation surrounding bronchus and bronchioli(peribronchiolitis) and 3) inflammation in the alveoli (alveolitis). Theaverage sum of the scores of all animals in one group created thepathology index (maximum score 15) (FIG. 4c , table 2). Lung pathologyafter RSV infection was significantly reduced in animal groups treatedwith high doses of immunoglobulin (2 mg kg⁻¹)(table 3). However only inthe AM14, AM22 and AM23 groups the pathology was significantly reducedat lower concentrations (0.4 mg kg⁻¹). While a complete absence ofpathology was seen in 3 out of 5 animals treated with AM22 and AM23 at 2mg kg⁻¹, at 0.4 mg kg⁻¹ complete protection was detected in 2 or 1 outof 5 animals in the AM14 and AM22 groups respectively (table 3).

When combining the results of examples 1, 2 and 3 it is concluded thatAM22 has certain advantages. AM22 demonstrates the lowest IC₅₀ value,meaning that with a lower amount of AM22 similar prophylactic ortherapeutic effects are achieved as compared with other antibodies. AM22recognizes a different epitope of the RSV F protein than the otherantibodies and therefore can be used in combination with one of theother antibodies to achieve a stronger immunogenic response to RSV andhigher antibody specificity against RSV. Finally, treatment of Cottonrats with AM22 resulted in nearly complete inhibition of virusreplication with potential complete absence of pathology in these Cottonrats.

Example 4: Affinity of AM22 for the RSV F Protein

Determining the affinity constant and specificity of binding between theRSV F protein and AM22 is preferred to establish the prophylactic,therapeutic and diagnostic value of the antibody. This is a challengingfeature since the antibody affinity has to be determined for anoligomeric protein structure. Usually affinity constants are determinedagainst immobilized agents that are captured on a chip. However proteinF captured on a chip would not be recognized by the AM14, AM22, AM23 andD25 antibodies.

Method

“Binding affinity” generally refers to the strength of the sum total ofthe noncovalent interactions between a single binding site of a molecule(e.g., an antibody) and its binding partner (e.g., an antigen). Theaffinity of a molecule X for its partner Y can generally be representedby the equilibrium dissociation constant (Kd), which is calculated asthe ratio k_(off)/k_(on). Affinity can be measured by common methodsknown in the art, such as a surface plasmon resonance (SPR) assay.Affinities (KD), on-rates (ka) and off-rates (kd) will be measured bySPR analysis with the IBIS-iSPR instrument at IBIS Technologies BV(Hengelo, the Netherlands). Briefly, anti-RSV antibodies are immobilizedand purified RSV F protein (containing penta-HIS) is diluted and rateand affinity constants are measured by injection of at least threeserial dilutions of the protein.

Another set up in the IMIS-iSPR machine is to immobilize 1) ananti-penta HIS antibody on which the F-penta HIS protein is coupled or2) F-penta HIS protein is directly immobilized on the chip and thensamples on the chip are incubated with the AIMM antibodies to determinethe affinity constants.

TABLE 1 RSV neutralizing activity of purified IgGs. RSV A2^(a)palivizumab 152 D25 1.28 AM14 2.09 AM16 78.7 AM22 1.15 AM23 4.18

The IC₅₀ (ng/ml) values of the selected anti-RSV IgGs were determinedwith standard TCID₅₀ culture assay on HEp2 cells with the RSV A2 virus.

TABLE 2 Cumulative pathology score in Cotton rats. Pathology scoreantibody mg/kg (SEM) P values Palivizumab 2.0 3.20 (0.4) 0.0005Palivizumab 0.4 5.40 (0.8) <0.05 D25 2.0 3.40 (0.4) 0.0005 D25 0.4 5.83(1.0) 0.05 AM14 0.4 4.20 (0.8) 0.05 AM14 0.1 3.67 (1.2) 0.05 AM22 2.02.75 (0.8) 0.0005 AM22 0.4 4.00 (0.9) <0.05 AM23 2.0 2.40 (0.2) 0.0005AM23 0.4 3.50 (0.9) <0.05 Ctrl IgG1 2.0 8.80 (1.1) N.A. MOCK N.A. 1.80(0.4) 0.0005

Cumulative pathology score of the lungs of Cotton rats, treated 24 hourbefore RSV infection with the indicated antibodies. Lung specimensobtained Ft days after infection were evaluated by a pathologistrandomly. Lungpathology was classified with scores between 0-5 for threeindividual markers: 1) hyperthropy of bronchus and bronchioli epithelia.2) peribronchiolitis and 3) alveolitis. Average pathology score (maximumscore 15) with standard error of the mean SEM) and statisticaldifferences in relation to Ctrl IgG1 group was calculated with the2-sided Wilcoxon test. Experiments were performed twice with four to sixindividual animals per treatment group. N.A. not applicable.

TABLE 3 Prevention of pathology in Cotton rats. Significant reductionantibody mg/kg in pathology No pathology Palivizumab 2 5/5 1/5Palivizumab 0.4 3/5 0/6 D25 2 5/5 0/5 D25 0.4 2/6 0/6 AM14 0.4 5/6 2/6AM14 0.1 4/5 0/5 AM22 2 5/5 3/5 AM22 0.4 5/6 1/6 AM23 2 5/5 3/5 AM23 0.45/6 0/6

Number of animals with significant reduction in/or absence of lungpathology at day 5 during RSV-X infection. Experiments were performedtwice with four to six individual animals per treatment group.

1. An isolated, synthetic or recombinant antibody or a functional part,derivative and/or analogue thereof which is capable of specificallybinding Respiratory Syncytial Virus and which comprises: a heavy chainCDR1 sequence comprising a sequence which is at least 70% identical tothe sequence KLSIH, and/or a heavy chain CDR2 sequence comprising asequence which is at least 70% identical to the sequenceGYEGEVDEIFYAQKFQH, and/or a heavy chain CDR3 sequence comprising asequence which is at least 70% identical to the sequenceLGVTVTEAGLGIDDY, and/or a light chain CDR1 sequence comprising asequence which is at least 70% identical to the sequence RASQIVSRNHLA,and/or a light chain CDR2 sequence comprising a sequence which is atleast 70% identical to the sequence GASSRAT, and/or a light chain CDR3sequence comprising a sequence which is at least 70% identical to thesequence LSSDSSI.
 2. An antibody, functional part, derivative oranalogue according to claim 1, having a heavy chain sequence comprisinga sequence which is at least 70% identical to the sequenceQVQLVQSGAEVKKPGATVKVSCKISGHTLIKLSIHWVRQAPGKGLEWMGGYEGEVDEIFYAQKFQHRLTVIADTATDTVYMELGRLTSDDTAVYFCGTLGVTVTEAGLGIDDYWGQ GTLVTVSSand/or having a light chain sequence which is at least 70% identical tothe sequenceEIVLTQSPGTLSLSPGERATLSCRASQIVSRNHLAWYQQKPGQAPRLLIFGASSRATGIPVRFSGSGSGTDFTLTINGLAPEDFAVYYCLSSDSSIFTFGPGTKVDFK.
 3. An antibody,functional part, derivative or analogue according to claim 1, which isconjugated to PEG or Albumin, and/or which comprises: a salvage receptorbinding epitope, and/or; modified amino acid residues identified asinvolved in the interaction between an Fc and an FcRN receptor, and/ornon naturally occurring amino acid residues.
 4. An antibody, functionalpart, derivative or analogue according to claim 1, comprising an Fcregion which comprises a modification at one or more positions selectedfrom the group consisting of 234, 235, 236, 237, 238, 239, 240, 241,243, 244, 245, 247, 251, 252, 254, 255, 256, 262, 263, 264, 265, 266,267, 268, 269, 279, 280, 284, 292, 296, 297, 298, 299, 305, 313, 316,325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 339, 341, 343, 370,373, 378, 392, 416, 419, 421, 440 and 443 as numbered by the EU index asset forth in Kabat et al, said modification comprising an amino acidsubstitution, and/or an amino acid insertion, and/or an amino aciddeletion.
 5. An isolated, synthetic or recombinant antibody or afunctional part, derivative and/or analogue thereof which is capable ofspecifically binding an epitope that is recognized by an antibody ofclaim
 1. 6. An antibody, functional part, derivative or analogueaccording to claim 5, wherein said antibody, functional part, derivativeor analogue has a dissociation constant (K_(d)) of less than 1×10⁻²M,1×10⁻³M, 1×10⁻⁴M, 1×10⁻⁵M, 1×10⁻⁶M, 1×10⁻⁷M, 1×10⁻⁸M, 1×10⁻⁹M, 1×10⁻¹⁰M, 1×10⁻¹¹M, 1×10⁻¹²M, 1×10⁻¹³M, 1×10⁻¹⁴M or less than 1×10⁻¹⁵ M. 7-8.(canceled)
 9. An isolated, synthetic or recombinant nucleic acidsequence, or a functional equivalent thereof, comprising a sequenceencoding an amino acid sequence which has at least 70% sequence identityto the sequence KLSIH, and/or at least 70% sequence identity to thesequence GYEGEVDEIFYAQKFQH, and/or at least 70% sequence identity to thesequence LGVTVTEAGLGIDDY, and/or at least 70% sequence identity to thesequence RASQIVSRNHLA, and/or at least 70% sequence identity to thesequence GASSRAT, and/or at least 70% sequence identity to the sequenceLSSDSSI, and/or at least 70% sequence identity to the sequenceQVQLVQSGAEVKKPGATVKVSCKISGHTLIKLSIHWVRQAPGKGLEWMGGYEGEVDEIFYAQKFQHRLTVIADTATDTVYMELGRLTSDDTAVYFCGTLGVTVTEAGLGIDDYWGQ GTLVTVSS,and/or at least 70% sequence identity to the sequenceEIVLTQSPGTLSLSPGERATLSCRASQIVSRNHLAWYQQKPGQAPRLLIFGASSRATGIPVRFSGSGSGTDFTLTINGLAPEDFAVYYCLSSDSSIFTFGPGTKVDFK.
 10. An isolated,synthetic or recombinant nucleic acid sequence with a length of at least15 nucleotides, or a functional equivalent thereof, encoding at leastone CDR sequence of an antibody or a functional part, derivative and/oranalogue thereof according to claim
 1. 11-12. (canceled)
 13. Anisolated, synthetic or recombinant nucleic acid sequence, or afunctional equivalent thereof, encoding at least one CDR sequencecapable of specifically binding an epitope that is recognized by anantibody which comprises: a heavy chain CDR1 sequence comprising thesequence KLSIH, and/or a heavy chain CDR2 sequence comprising thesequence GYEGEVDEIFYAQKFQH, and/or a heavy chain CDR3 sequencecomprising the sequence LGVTVTEAGLGIDDY, and/or a light chain CDR1sequence comprising the sequence RASQIVSRNHLA, and/or a light chain CDR2sequence comprising the sequence GASSRAT, and/or a light chain CDR3sequence comprising the sequence LSSDSSI. 14-15. (canceled)
 16. A vectorcomprising a nucleic acid sequence or functional equivalent according toclaim
 9. 17. An isolated or recombinant cell comprising a nucleic acidsequence or functional equivalent according to claim
 9. 18-19.(canceled)
 20. A combination comprising: an antibody, functional part,derivative or analogue according to claim 1, and a differentRSV-specific agent, preferably an antibody. 21-22. (canceled)
 23. Acombination according to claim 20 wherein said different RSV-specificagent is Palivizumab, and/or AM14 and/or AM16, and/or AM23, and/or D25.24. Use of an antibody, functional part, derivative or analogueaccording to claim 1 for the preparation of a medicament and/orprophylactic agent for at least in part treating and/or preventing aRSV-related disorder.
 25. A pharmaceutical composition comprising: anantibody, functional part, derivative or analogue according to claim 1and a pharmaceutical acceptable carrier, diluent or excipient.
 26. Anisolated or recombinant antibody producing cell capable of producing anantibody, functional part, derivative or analogue according to claim 1.27. A method for producing an antibody, functional part, derivative oranalogue, comprising providing a cell with a nucleic acid sequence orfunctional equivalent according to claim 9 and allowing said cell totranslate said nucleic acid sequence or functional equivalent therebyproducing said antibody, functional part, derivative or analoguethereof.
 28. A method according to claim 27, further comprisingharvesting, purifying and/or isolating said antibody, functional part,derivative or analogue thereof.
 29. Use of a nucleic acid sequence orfunctional equivalent according to claim 9 for the preparation of amedicament and/or prophylactic agent for at least in part treatingand/or preventing a RSV-related disorder.
 30. Use of a combinationaccording to claim 20 for the preparation of a medicament and/orprophylactic agent for at least in part treating and/or preventing aRSV-related disorder.